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Resection of musculoskeletal sarcoma can result in large bone defects where regeneration is needed in a quantity far beyond the
normal potential of self-healing. In many cases, these defects exhibit a limited intrinsic regenerative potential due to an adjuvant
therapeutic regimen, seroma, or infection.erefore, reconstruction of these defects is still one of the most demanding procedures
in orthopaedic surgery. e constraints of common treatment strategies have triggered a need for new therapeutic concepts to
design and engineer unparalleled structural and functioning bone gras. To satisfy the need for long-term repair and good clinical
outcome, a paradigm shi is needed from methods to replace tissues with inert medical devices to more biological approaches
that focus on the repair and reconstruction of tissue structure and function. It is within this context that the �eld of bone tissue
engineering can oﬀer solutions to be implemented into surgical therapy concepts aer resection of bone and so tissue sarcoma.
In this paper we will discuss the implementation of tissue engineering concepts into the clinical �eld of orthopaedic oncology.
1. Introduction
Bone has to carry major loads. To ful�l this task it is
created as a composite material, which comprises primarily
of collagen, noncollageneous proteins, and hydroxyapatite.
Its complex structure contains a wealth of mechanically
relevant details [1]. Bone is a composite in several senses
that is, being a porous material, a polymer-ceramic mixture,
a lamellar material, and a �bre-matrix material. Its mechani-
cal properties will therefore depend on each of these aspects
of composition and structure. In general, bone displays a high
intrinsic regenerative capacity following trauma or disease.
erefore, the majority of fractures heal spontaneously by a
recapitulation of the pathway of normal fetal skeletogenesis,
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including endochondral and intramembraneous ossi�cation
[4]. �e�nements in surgical techniques, implant design and
postoperative care have signi�cantly improved treatment
outcomes of complex fractures and defects as caused by high-
energy trauma, disease, developmental deformity, and revi-
sion surgery. However, there are conditions in which bone
regeneration is compromised or in which bone regeneration
is required in a large quantity.
A situation of the latter entity is the resection ofmalignant
bone and so tissue sarcoma. is can result in large defects
where regeneration is needed in a quantity far beyond
the normal potential of self-healing [5]. Furthermore, an
adjuvant therapeutic regimen or local factors such as postop-
erative seroma or infection can account for a limited intrinsic
regenerative potential [6]. erefore, reconstruction of these
defects is still one of the most demanding procedures in
orthopaedic surgery.
2. Common Treatment Strategies for
Bone Defects
Treatment protocols of bone and so tissue sarcoma are based
not only on the tumour biology and location, but also on the
patient’s needs and age [7]. e primary surgical goal should
be to obtain adequate surgical margins in order to ensure
local tumor control [8–10]. With the introduction of mul-
timodal therapeutic concepts and improved reconstruction
techniques, limb salvage procedures have largely replaced
ablative surgery [11–14], but only few of them can restore
the original anatomical and functional conditions. For the
reconstruction of skeletal defects aer tumor resection, both
biological techniques (e.g., autogras, allogras, or rotation-
plasty) and prostheses are used. ese procedures, mainly
bone graing and metallic implants, are well established and
the comparative advantages and disadvantages have been
discussed at length in the literature [15–17]. Problems of
autologous bone graing can be donor site morbidity and
limitation of the gra mass. For gra harvesting, additional
personnel and time are needed. e use of allogras or
xenogras carries the risk of immunomediated rejection,
transmission of infectious diseases, or gra sequestration.
In addition, the acquisition costs of allo- or xenogras are
rather high. Gra devitalisation and consecutive absorp-
tion processes can lead to decreased mechanical stability.
Failures usually result from incomplete transplant integra-
tion, particularly in critical sized defects. Due to the dense
nature of cortical allogras, revascularisation and cellular
invasion is impeded. is limited ability for revasculariza-
tion and remodelling is believed to be responsible for the
high complication rate associated with allogras [18]. Other
biologic approaches used for the reconstruction of bone
defects include distraction osteogenesis, segment transport,
or the Masquelet technique, but all of these methods are
technically demanding and they require lengthy treatment
protocols, which can be highly inconvenient for patients
[19, 20]. e limitations of these conventional biological
reconstruction techniques are exacerbated in cancer patients,
who are oen elderly, have localised or systemic osteoporosis
and suﬀer from impaired wound healing as a consequence of
an adjuvant therapeutic regimen. e high tensile strength
and fatigue resistance of metal would make it suitable for
load-bearing applications, but the large mismatch in Young’s
modulus between metal and bone can lead to peri-implant
bone resorption, a phenomenon known as stress shielding
[21]. Furthermore, tumor endoprostheses exhibit a higher
complication rate than standard implants with infection or
aseptic loosening as the most common failure modes [22].
ese constraints have triggered a need for new therapeu-
tic concepts to design and engineer unparalleled structural
and functioning bone gras to replace current treatment
options. To satisfy the need for long-term repair and good
clinical outcome, a paradigm shi is needed frommethods to
replace tissues with inert medical devices to more biological
approaches that focus on the repair and reconstruction of
tissue structure and function [23]. It is within this context
that the �eld of bone tissue engineering can oﬀer solutions to
be implemented into surgical therapy concepts aer resection
of bone and so tissue sarcoma. While this has already led
to a variety of novel therapeutic concepts particularly in the
�eld of craniofacial surgery [3, 24], only few called smart
biomaterials have found their way into clinical application in
the �eld of orthopaedic surgery.
In the following passages, we will discuss the implemen-
tation of tissue engineering concepts into treatment strategies
of bone defects caused by musculoskeletal sarcoma. From
a material science and especially clinical point of view, the
future prospects and possible application spectrum will be
outlined.
3. Tissue Engineering Constructs (TECs)
e �eld of tissue engineering is embodied in the collective
vision of its early pioneers Langer and Vacanti, whose diverse
yet symbiotic research approaches as an engineer and surgeon
led to the commencement of this interdisciplinary �eld.eir
seminal 1993 paper remains one of the most in�uential and
cited works in the �eld [25]. e application of the principles
of biology and engineering to the development of functional
substitutes for damaged tissue has seen laboratories world-
wide forging impressive multidisciplinary teams to focus on
restoring, maintaining, or improving the function of a wide
range of human tissues. While progress has been made to
deliver bench to bedside solutions, the rate at which tissue
engineering has seen innovations translated to the clinic
has been slower than originally expected and the urgency
for tissue-engineered products which achieve these ideals
remains high [26–28].
e fundamental concept underlying tissue engineering
is to combine a scaﬀold with living cells and/or biologically
active molecules to form a “tissue engineering construct”
(TEC) which promotes the repair and/or regeneration of
tissues [29, 30]. A suitable scaﬀold should (i) possess a
porous interconnected pore network (pores and pore inter-
connections should be at least 400𝜇𝜇m to allow vascularisa-
tion) with surface properties optimised for the attachment,
migration, proliferation, and diﬀerentiation of cell types
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F 1: Schematic illustrating the interdependence of molecular weight loss and mass loss of a slow-degrading composite scaﬀold plotted
against time. Scaﬀold implanted at 𝑡𝑡 𝑡 𝑡 with lower �gures showing a conceptual illustration of the biological processes of bone formation
over time. A�er implantation the scaﬀold is immediately �lled with haematoma followed by vascularisation. �ew bone is formed gradually
within the scaﬀold. As the scaﬀold degrades over time, there is increased bone remodelling within the implant site until the scaﬀold pores are
entirely �lled with functional bone and vascularity (partially adapted from �2�).�e lower part of the �gure shows the schematic visualisation
of how medical-grade poly-𝜀𝜀-caprolactone/tricalcium phosphate (mPCL-TCP) degrades via long-term bioerosion processes.
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(a)
(b)
(c)
F 2: 34 year old patient with a large destructive so tissue
mass of the right hemipelvis. Coronal T1-weighted (a) and axial T2-
weighted (b) MRI images demonstrate calci�c lobules and punctu-
ated foci with low signal intensity representing calci�cations, which
are typical for chondroid matrix. Histological analysis revealed a
dediﬀerentiated chondrosarcoma. Aer resection of the aﬀected
bone a custom-made pelvic metal prosthesis was �tted into the
defect. Radiograph one year postoperatively (c) shows a stable
prosthesis, the functional and clinical outcome of the patient was
good.
of interest (depending on the targeted tissue) and enable
�ow transport of nutrients and metabolic waste, (ii) be
biocompatible, and (iii) be biodegradable with a controllable
rate to complement cell/tissue growth and maturation [23,
31]. e design of these scaﬀolds also needs to consider
physicochemical properties and morphology. External size
and shape of the construct are of importance, particularly
if the construct is customised for an individual patient. e
work by groups focussing on scaﬀold design and fabrication
utilising additive manufacturing technologies has advanced
the tissue engineering �eld tremendously over the past few
years [32]. e ability to create scaﬀolds in a layer-by-
layer manner enables a computer-aided design to be directly
translated from a clinical scan (i.e., a patient CT orMRI scan)
to produce customised and/or patient-speci�c scaﬀolds to �t
any anatomical defect site [33, 34].
4. Regeneration and Remodelling of TECs
Aer scaﬀold implantation, continuous cell and tissue
remodelling is essential to achieve and maintain stable
biomechanical conditions, vascularization, and integration
within the host site [2]. Importantly, TECs should stimulate
and support both the onset and the continuance of bone
ingrowth as well as subsequent remodelling and maturation
by providing optimal stiﬀness and external and internal
geometrical shapes. Scaﬀolds must provide suﬃcient initial
mechanical strength and stiﬀness to substitute for the loss
of mechanical function of the diseased, damaged, or missing
tissue. Furthermore TECs must degrade at a rate which is
compatible with new tissue ingrowth and maturation [35].
It is essential to understand and control this scaﬀold degra-
dation process for successful tissue formation, remodelling
and maturation at the defect site. In the early days of tissue
engineering, it was believed that scaﬀolds should degrade
and vanish as the tissue is growing [36]. ough, tissue
ingrowth and maturation diﬀer temporally from tissue to
tissue and, furthermore, tissue ingrowth does not equate to
tissue maturation and remodelling. In other words, a defect
�lled with an immature tissue should not be considered as
“regenerated.” Hence, many scaﬀold-based strategies have
failed in the past as scaﬀold degradation was more rapid than
tissue remodelling and/or maturation [37]. Our concept of
using a slow degrading composite scaﬀold fabricated with
pores and pore interconnections with a size larger than
400 𝜇𝜇m is illustrated in Figure 1.
5. Translating Bone Tissue
Engineering Concepts into the Clinical Field
of Orthopaedic Oncology
Bone defects aer resection of musculoskeletal tumours
represent a considerable surgical challenge, are associated
with high socioeconomic costs and highly in�uence patients�
quality of life. ese problems may be approached from the
perspective of the nature of the gra material with which the
surgeon works. e mission of our interdisciplinary group
is to coordinate eﬀorts between researchers and clinicians
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F 3: Side and top view of a PCL scaﬀold for tibia segmental defect regeneration, visualised by microcomputed tomography. e
fabrication technique results in scaﬀolds with well-controlled architecture as evidenced by the narrow �lament thickness distribution, leading
to a porosity (volume fraction available for tissue ingrowth) of 60%, with interconnected pores. Scale bars are 5mm.
in the area of bone tissue engineering and the translation of
tissue engineering platforms into orthopaedic oncology. Lab-
oratories in Singapore, Germany, and Australia have spent
the last decade in close collaboration translating a concept
of bone tissue engineering based on slowly biodegradable
composite scaﬀolds comprising medical grade poly (epsilon-
caprolactone) (mPCL) and calcium phosphates from bench
to bedside [38–45]. Aer a large series of in vitro experiments,
we consequently performed small animal studies using
mouse, rat, and rabbit models which demonstrated the ability
of composite scaﬀolds in combination with BMPs or cells
to promote bone regeneration within ectopic sites or bone
defects [35]. Another key project of our group has been the
development of a large animal model for bone regeneration
research.We recently have established and fully characterised
a critically sized defect model in sheep tibiae to evaluate
diﬀerent tissue-engineering-based treatment strategies [46,
47].
In the following section, we will describe a part of the
rationale and roadmap of how ourmultidisciplinary research
team is approaching the �rst steps to translate bone tissue
engineering concepts into orthopaedic oncology.
Our clinical partners have used custom-made metal
prostheses for the treatment of pelvic defects aer sarcoma
resection for more than 20 years [48, 49]. Since 1988, the
general production process of the prosthesis has only changed
in details but has developed according to the technological
advances available. In the �rst step a 1 : 1 pelvicmodel ismade
using data acquired via high-resolution computed tomogra-
phy. e model is cut out from a block of polyurethane by a
�ve axial C�C-milling machine. In the next step the surgeon
uses this model to de�ne the levels of osteotomy with special
regard to the later surgical margins. According to the planned
osteotomy planes and the acquired CT-data not only the
custom-made prosthesis but also special osteotomy guides
are constructed by themanufacturer to ensure accurate �tting
of the prosthesis. e series reported from our institution
showed encouraging results (Figure 2) [50].
Although these massive endoprostheses provide ortho-
paedic oncologists with many reconstructive options, fail-
ure rates are still high. Especially in younger patients a
reconstructive method would be desirable that does not
rely on the use of permanent metal implants but rather
on bioactive materials enabling customised reconstruction
and supporting natural healing processes. Using computer-
aided design (CAD) and fused deposition modelling (FDM)
technologies, we are able to produce bioresorbable composite
scaﬀolds fabricated from mPCL, either with or without rein-
forcement using up to 20wt% 𝛽𝛽-tricalcium phosphate (TCP)
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(a) (b)
(c) (d)
F 4: Clinical application of a cell-free polycaprolactone-calcium phosphate scaﬀold for bone regeneration in a calvarial defect. Scaﬀold
designed using CT imaging data and fabricated by fused depositionmodeling (a). Calvarial defect (b). Defect aer implantation of the scaﬀold
(c). CT images showing bony consolidation of the defect aer 6 months (d). Reproduced with permission from Georgieme Verlag (2012)
[3].
for bone tissue engineering applications at load-bearing sites
(Figure 3).
is scaﬀold exhibits mechanical and structural proper-
ties comparable to cancellous bone and can be speci�cally
adapted to the clinical needs with a fully interconnected
pore network structure [45, 51]. A detailed description of
the fabrication protocol has been given elsewhere [34, 39,
44]. ese scaﬀolds are already in clinical use and are FDA
approved for craniofacial applications [3] (Figure 4).
In principle, the fabrication process of our scaﬀolds as
depicted in Figure 5 is similar to that described for the
patient-speci�c and individually customised pelvic metal
implants. Preoperatively, high-resolution CT data is pro-
cessed via a 3Dmedical imaging soware (e.g., InVesalius 3.0)
supporting the medical DICOM/PACS format to generate
a virtual model of the pelvis. In the next step, the data set
is converted into a Standard Tessellation Language format
(STL) which is the standard format for rapid prototyping
applications. Accordingly, a model is built from an acryloni-
trile butadiene styrene (ABS) polymer using a 3D fabricator
(FDM3000, Stratasys, Eden Prairie, USA) based on fused
deposition modeling technology. e model facilitates the
haptic perception and orientation both before and during
surgery. In close collaboration with the orthopaedic surgeon,
the levels of osteotomy are marked in both the virtual and the
physical model. Considering the dimensions of the tumor it
should be possible to achieve tumor-free resection margins.
As it has been previously described for the customised
metal implants [50], based on the virtual model, special
osteotomy guides can be manufactured to facilitate the later
resection and implantation process of the scaﬀold. As the
dimensions of the prospective bony defect are exactly known,
the dimensions of the scaﬀold can be virtually adjusted.
Moreover, the form of the scaﬀold can be adapted to the
clinical needs. In the �rst step, we mirror the healthy side of
the pelvis to the aﬀected one to achieve near-physiological
conditions. Aerwards the scaﬀold is armed with �anges
and an intramedullary peg to improve its primary stability.
en, Skeinforge soware is employed to generate the print-
ing toolpath, which is subsequently modi�ed to introduce
porosity allowing tissue ingrowth. An in�ll density of 0.2
is chosen, corresponding to 80% porosity. Furthermore, the
perimeter sections of the toolpath are removed using a
custom algorithm to generate open pores to the exterior of
the scaﬀold. According to this modi�ed toolpath the scaﬀold
is then manufactured using again a 3D fabricator. We used a
commercially available MakerBot Replicator with poly(D,L-
lactide (PDLLA) as biomaterial. PDLLA is a biodegradable
thermoplastic polymer which has been successfully applied
for �xation in maxillofacial reconstructions before [52, 53]
and has been made available for several additive man-
ufacturing techniques such as fused deposition modeling
(as in this application) and stereolithography [54]. During
surgery, the �anges are �xed with resorbable tacks or screws.
Additionally, the contact area between the scaﬀold and the
host bone can be covered with �brin glue which can serve
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F 5: Schematic illustration of the scaﬀold manufacturing process. A 3D computer-aided designed (CAD) model of the patient’s pelvis
is fabricated according to data obtained by high-resolution CT ((a), (b)). Using this prototype, the surgeon indicates the osteotomy planes
needed to achieve tumour-free resection margins, aer which the CADmodel is virtually resected ((c), (d)). A scaﬀold model is then derived
by mirroring the healthy side of the pelvis and ad�usting the si�e to �t into the defect ((e), (f)). �e scaﬀold can be armed with �anges or
an intramedullary peg to enhance its primary stability ((g), (h)) and exhibits a porous internal architecture to allow for tissue ingrowth and
regeneration (i).
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F 6: In orthopaedic oncology, vascularised �bula transfer
is considered as one of the most suitable techniques for the
reconstruction of critically sized defects of the tibia diaphysis due
to the mechanical strength, the predictable vascular pedicle, and
the hypertrophic potential of the �bula. Combining the autogra
with a large bone allogra can enhance the biomechanical properties
of the construct. However, the use of allogras can be associated
with signi�cant drawbacks such as immunomediated rejection, gra
sequestration or transmission of infectious diseases. In addition,
the acquisition costs are rather high. A novel biological approach
could be to combine an intramedullary �bular autogra with a
customised tissue engineered bone construct. Aer tumor resection
(a) a customised mPCL/TCP tube is placed around the vascularised
�bula (b) to �ll the defect. Together with an internal �xation
device, it ensures load distribution and primary stability. Secondary
stability is achieved by osseointegration of both the �bula and the
porous scaﬀold (c).
as a biomimetic template promoting migration of osteogenic
cells.
e presented therapy strategy combines the advantages
of both CAD/CAM procedures and tissue engineering con-
cepts. Technically, it is not restricted to the application in
defects caused by pelvic tumors but can also be transferred
to other bony defect sites (Figure 6).
6. Outlook
ough, small bony defects such as cysts are relatively easy to
handle in the routine clinical setting, themanagement of large
defects in load-bearing bones presents a particular challenge
in reconstructive surgery and particularly in orthopaedic
oncology. In this opinion paper, tissue engineering has been
suggested as an alternative strategy to regenerate bone in
patients with musculoskeletal sarcoma. We have developed
an integrated holistic approach for the reconstruction of bone
defects caused by musculoskeletal tumours using patient-
speci�c scaﬀolds with well-de�ned macro- and microarchi-
tecture. ough promising case reports have been presented
in the literature [3, 55], large clinical studies, which can
show the eﬃcacy of this approach in the clinical setting, are
still missing. To tackle major bone tissue engineering prob-
lems in orthopaedic oncology, researchers have to perform
functional assessment of the biological and biomechanical
parameters of the regenerated bone. Furthermore, to allow
a comparison between diﬀerent studies, animal models,
�xation devices, surgical procedures, and methods of taking
measurements need to be standardised to achieve an eﬃcient
accumulation of reliable data as a foundation for future
developments.
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